| Size | Price | Stock | Qty |
|---|---|---|---|
| 100mg |
|
||
| 500mg |
|
||
| Other Sizes |
| Targets |
DSPE-PEG-Amine does not have a specific biological receptor target. It functions as a lipid excipient for the formulation of liposomes and nanoparticles. The DSPE moiety anchors the molecule into lipid bilayers, while the PEG chain provides a hydrophilic, sterically stabilizing "stealth" layer that reduces opsonization and prolongs circulation time. The terminal amine group can be used for further functionalization, enabling the creation of targeted drug delivery systems.
|
|---|---|
| ln Vitro |
In vitro, DSPE-PEG-Amine is used in the preparation of liposomes for drug delivery applications. The amine group can be converted into aromatic aldehydes and reacted with acetone-protected aromatic hydrazines on the surface of proteins, such as bovine carbonic anhydrase (BCA), to form bis-aryl hydrazone (BAH) conjugates. This chemistry allows for the creation of liposome-protein conjugates for catalytic or therapeutic applications.
|
| ln Vivo |
In vivo, DSPE-PEG-Amine-containing liposomes and nanoparticles are used for drug delivery applications. The DSPE-PEG component has been used in FDA-approved drug delivery systems. The PEG component improves circulation time and stability, while the amine group enables conjugation of targeting ligands for active targeting. However, the compound itself is an excipient and does not have intrinsic biological activity.
|
| Enzyme Assay |
In vitro assays for DSPE-PEG-Amine typically involve characterizing the formation and functionalization of liposomes or nanoparticles. Liposomes are prepared by dissolving the lipid components, including DSPE-PEG-Amine, in organic solvent, followed by solvent removal and hydration. The successful incorporation of the PEG-lipid and the availability of the amine group for conjugation can be verified by methods such as dynamic light scattering (DLS) for size and zeta potential, and by using colorimetric assays (e.g., TNBS assay) to quantify the amine groups on the particle surface.
|
| Cell Assay |
In vitro cellular assays for DSPE-PEG-Amine are typically performed as part of drug delivery studies. Cells are treated with liposomes or nanoparticles formulated with DSPE-PEG-Amine, and their uptake, cytotoxicity, and therapeutic efficacy are assessed. The amine group can be used to conjugate fluorescent probes or targeting ligands to track cellular uptake and targeting efficiency.
|
| Animal Protocol |
In vivo animal studies for DSPE-PEG-Amine-containing formulations typically involve the administration of the nanoparticles to rodent models to assess their pharmacokinetics, biodistribution, and therapeutic efficacy. The PEG component is known to prolong circulation time, and targeting ligands can enhance accumulation at target sites.
|
| ADME/Pharmacokinetics |
DSPE-PEG-Amine is a PEGylated lipid with an average molecular weight of approximately 10,000 Da. It is supplied as an ammonium salt and is soluble in ethanol and DMSO. The compound is typically stored as a powder at -20°C for up to 3 years or in solution at -80°C for up to 6 months. Detailed pharmacokinetic parameters are not applicable as the compound is an excipient.
|
| Toxicity/Toxicokinetics |
There is no specific toxicity data reported for DSPE-PEG-Amine. As a research chemical, it should be handled with standard safety precautions. The DSPE-PEG component is generally considered biocompatible and has been used in FDA-approved formulations.
|
| References |
[1]. Nagata H, et al. Preparation and Catalytic Properties of Carbonic Anhydrase Conjugated to Liposomes through a Bis-Aryl Hydrazone Bond. ACS Omega. 2023 May 16;8(21):18637-18652.
|
| Additional Infomation |
DSPE-PEG-Amine (MW 10000) is a functionalized phospholipid-polymer conjugate used in the preparation of liposomes for drug delivery. It has an average molecular weight of approximately 10,000 Da and is supplied as an ammonium salt. The terminal amine group allows for bioconjugation, enabling the creation of targeted delivery systems.
|
| Molecular Formula |
(C2H4O)NN2O10P.NH3
|
|---|---|
| Molecular Weight |
10000(Average)
|
| Exact Mass |
895.662
|
| CAS # |
474922-26-4
|
| PubChem CID |
156592378
|
| Appearance |
White to off-white solid powder
|
| LogP |
0
|
| Hydrogen Bond Donor Count |
4
|
| Rotatable Bond Count |
50
|
| Heavy Atom Count |
61
|
| Complexity |
1020
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
0
|
| InChi Key |
AXHRCGLQEUQOIS-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C46H91N2O11P.H3N/c1-3-5-7-9-11-13-15-17-19-21-23-25-27-29-31-33-44(49)56-41-43(42-58-60(52,53)57-38-36-48-46(51)55-40-39-54-37-35-47)59-45(50)34-32-30-28-26-24-22-20-18-16-14-12-10-8-6-4-2;/h43H,3-42,47H2,1-2H3,(H,48,51)(H,52,53);1H3
|
| Chemical Name |
azanium;2-[2-(2-aminoethoxy)ethoxycarbonylamino]ethyl 2,3-di(octadecanoyloxy)propyl phosphate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
Ethanol : ~16.67 mg/mL
DMSO : ~7.14 mg/mL |
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
